TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

TG Therapeutics (NASDAQ:TGTX) First Quarter 2025 Results

Key Financial Results

• Revenue: US$120.9m (up 90% from 1Q 2024).
• Net income: US$5.06m (up from US$10.7m loss in 1Q 2024).
• Profit margin: 4.2% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
• EPS: US$0.034 (up from US$0.073 loss in 1Q 2024).

We check all companies for important risks. See what we found for TG Therapeutics in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

TG Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 82%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 10% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on TG Therapeutics' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.